Cargando…
Potential Risk of Other-Cause Mortality Due to Long-Term Androgen Deprivation Therapy in Elderly Patients with Clinically Localized Prostate Cancer Treated with Radiotherapy—A Confirmation Study
Androgen deprivation therapy (ADT) is used to improve overall survival (OS) in prostate cancer treatment; however, we encountered that long-term ADT in elderly patients may be related to high other-cause mortality (OCM). This study aimed to confirm the potential risk associated with long-term ADT in...
Autores principales: | Yamazaki, Hideya, Masui, Koji, Suzuki, Gen, Aibe, Norihiro, Shimizu, Daisuke, Kimoto, Takuya, Yoshida, Ken, Nakamura, Satoaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408941/ https://www.ncbi.nlm.nih.gov/pubmed/32698307 http://dx.doi.org/10.3390/jcm9072296 |
Ejemplares similares
-
Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
por: Yamazaki, Hideya, et al.
Publicado: (2021) -
Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021) -
Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022) -
Effect of Androgen Deprivation Therapy on Other-Cause of Mortality in Elderly Patients with Clinically Localized Prostate Cancer Treated with Modern Radiotherapy: Is There a Negative Impact?
por: Yamazaki, Hideya, et al.
Publicado: (2019) -
Comparison of toxicities between ultrahypofractionated radiotherapy versus brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022)